

## RECEIVED

## PART B - FEE(S) TRANSMITTAL

JUL 08 2003

(s), to: <u>Mai</u>
4

il Mail Stop ISSUE FEE

Commissioner for Patents

Alexandria, Virginia 22313-1450 API LEGAL DEPT

INSTRUCTIONS: The form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks I through 4 should be completed where appropriate. All further correspondence including the Patent, advance orders and nonlifection of maintenance fees will be mailed to the current correspondence address as appropriate. All further correspondence including the Patent, advance orders and nonlifection of maintenance fees will be mailed to the current correspondence address; and/or (b) indicating a separate "FEE ADDRESS" for appropriate. All further correspondence including the Patent, advance orders and nonlifection of maintenance address; and/or (b) indicating a separate "FEE ADDRESS" for appropriate to the current correspondence address and nonlifection of maintenance address; and/or (b) indicating a separate "FEE ADDRESS" for appropriate to the current correspondence address as a separate "FEE ADDRESS" for appropriate to the current correspondence address and nonlifection of maintenance fees will be mailed to the current correspondence address; and/or (b) indicating a separate "FEE ADDRESS" for appropriate to the current correspondence address; and/or (b) indicating a separate "FEE ADDRESS" for appropriate to the current correspondence address; and/or (b) indicating a separate "FEE ADDRESS" for appropriate to the current correspondence address; and/or (b) indicating a separate "FEE ADDRESS" for appropriate to the current correspondence address; and/or (b) indicating a separate "FEE ADDRESS" for appropriate to the current correspondence address; and/or (b) indicating a separate "FEE ADDRESS" for appropriate to the current correspondence address; and/or (b) indicating a separate "FEE ADDRESS" for appropriate to the current correspondence address; and/or (b) indicating a separate "FEE ADDRESS" for appropriate to the current correspondence address; and/or (b) indicating a separate "FEE ADDRESS" for appropriate to the current correspondence address; and/or (b) indicating a separate "FEE ADDRESS" for appro

AGOURON PHARMACEUTICALS, INC. 10350 NORTH TORREY PINES ROAD LA JOLLA, CA 92037

Note: A certificate of mailing can only be used for domestic mailings of the Fee(9) Transmittal. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, must have its own certificate of mailing or transmission.

Certificate of Mailing or Transmission 1.10

I hereby certify that this Fee(s) Transmittal is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Box Issue Fee address above, or being facsimile transmitted to the USPTO, on the date indicated below.

Julie Agozi (Signatur Mostos October

CONFIRMATION NO. ATTORNEY DOCKET NO. FIRST NAMED INVENTOR 6657 PC10925A FILING DATE APPLICATION NO. Manoussos Perros 05/25/2001

TITLE OF INVENTION: TROPANE DERIVATIVES USEFUL IN THERAPY

11100	DATE DUE
ISSUE PEE	PUBLICATION FEE TOTAL FEE(S) DUE DATE DOL: \$1600 10/03/2003
APPLN. TYPE SMALL ENTITY	\$300
nonprovisional NO ART UNIT	CLASS-SUBCLASS
EXAMINER 1625	514-304000
HUANG, EVELYN MEI	2. For printing on the patent front page, list (1) the names of un tographysely. (2) the name of a  Dr. Peter Richard  Dr. Peter Richard  Reven C. Zielinsk
1. Change of correspondence address or indication of "Fee Address" (37	the names of up to 3 registered patent attributes of a grants OR, alternatively, (2) the name of a grants OR, alternatively, (2) the name of a Bryan C. Zielinsk

CFR 1.363).

Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached.

O "Fee Address" indication (or "Fee Address" Indication form PTO/SB/47; Rev 03-02 or more recent) attached. Use of a Customer Number is required.

or agents OR, alternatively, (2) the name of a single firm (having as a member a registered attorney or agent) and the names of up to 2 registered patent attorneys or agents. If no name is listed, no name will be printed.

Dr. Peter Richardson

Bryan C. Zielinski

3 Keith D. Hutchinson

PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. Inclusion of assignee data is only appropriate when an assignment has been previously submitted to the USPTO or is being submitted under separate cover. Completion of this form is NOT a substitute for filing an assignment.

ON DESIDEMAN OF ASSIGNEE. 3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type)

(A) NAME OF ASSIGNEE

New York, NY

O individual Corporation or other private group entity O government Pfizer, Inc. Please check the appropriate assignee category or categories (will not be printed on the patent) 4b. Payment of Fee(s): A check in the amount of the fee(s) is enclosed. 4a. The following fee(s) are enclosed:

M tense Fee

☐ Payment by credit card. Form PTO-2038 is attached.

Dathe Commissioner is hereby authorized by charge the required fee(s), or credit any overpayment, to Deposit Account Number 5000329 (enclose an extra copy of this form).

Commissioner for Patents is requested to apply the Issue Fee and Publication Fee (if any) or to re-apply any previously paid issue fee to the application identified above. Keith D. Hutchinson

NOTE: The Issue Fee and Publication Fee (if required) will not be accepted from anyone other than the applicant; a registered attorney or agent; or the assignee or other party in interest as shown by the records of the United States Patent and Trademark Office. (Authorized Signature)

interest as shown by the records of the United States Patent and Trademark Uffice.

This collection of information is required by 37 CFR 1.311. The information is required to obtain or retain a bearsfit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is explication. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is explication. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is explication. Complete complete complete the complete complete application form to the USPTO. Time will vary depending upon the individual complete application form to the USPTO. Time will vary depending upon the individual complete application form to the USPTO. Time will vary depending the form and/or case. Any comments on the amount of time you require to complete this form and/or sage stores for reducing this burden, should be sent to the Chief Information Officer, U.S. suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commence, Alexandria, Virginia 22313-1450.

SEND TO: Commissioner for Patents, Alexandria, Virginia 22313-1450.

Registration No. 43,687

03865950 10/03/5003 &ETERES 0000035 200353

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.